SG10201808208PA - Agent comprising imidazole dipeptide - Google Patents

Agent comprising imidazole dipeptide

Info

Publication number
SG10201808208PA
SG10201808208PA SG10201808208PA SG10201808208PA SG10201808208PA SG 10201808208P A SG10201808208P A SG 10201808208PA SG 10201808208P A SG10201808208P A SG 10201808208PA SG 10201808208P A SG10201808208P A SG 10201808208PA SG 10201808208P A SG10201808208P A SG 10201808208PA
Authority
SG
Singapore
Prior art keywords
agent
imidazole dipeptide
metabolite
group
neuropsychologic
Prior art date
Application number
SG10201808208PA
Inventor
Tatsuhiro Hisatsune
Mamoru Totsuka
Hideo Satsu
Jun Kaneko
Yoshinori Katakura
Mikako Sato
Takashi Matsumoto
Fumiki Morimatsu
Etsuko Imabayashi
Hiroshi Matsuda
Original Assignee
Univ Tokyo
Univ Kyushu Nat Univ Corp
Nh Foods Ltd
Nat Center Neurology & Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo, Univ Kyushu Nat Univ Corp, Nh Foods Ltd, Nat Center Neurology & Psychiatry filed Critical Univ Tokyo
Publication of SG10201808208PA publication Critical patent/SG10201808208PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/13—Dipeptidases (3.4.13)
    • C12Y304/1302—Beta-Ala-His dipeptidase (3.4.13.20)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Agent containing imidazole dipeptide An anti-aging agent derived from a natural product is provided. The agent uses at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for changing expression of a transporter such as SLC23A2, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, and an agent for controlling blood concentration of a cytokine such as IP-10, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, as well as an expression analysis method for detecting improvement or degradation of a neuropsychologic function, and a kit for detecting improvement or degradation of a neuropsychologic function. Figure 1
SG10201808208PA 2014-03-28 2015-03-04 Agent comprising imidazole dipeptide SG10201808208PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014069103 2014-03-28
JP2014142910A JP2015193582A (en) 2014-03-28 2014-07-11 Agent containing imidazoledipeptide

Publications (1)

Publication Number Publication Date
SG10201808208PA true SG10201808208PA (en) 2018-10-30

Family

ID=54195052

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608027RA SG11201608027RA (en) 2014-03-28 2015-03-04 Agent comprising imidazole dipeptide
SG10201808208PA SG10201808208PA (en) 2014-03-28 2015-03-04 Agent comprising imidazole dipeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608027RA SG11201608027RA (en) 2014-03-28 2015-03-04 Agent comprising imidazole dipeptide

Country Status (8)

Country Link
US (2) US20170165314A1 (en)
EP (1) EP3124034B1 (en)
JP (1) JP2015193582A (en)
KR (2) KR20220164079A (en)
CN (1) CN106413733A (en)
ES (1) ES2879329T3 (en)
SG (2) SG11201608027RA (en)
WO (1) WO2015146522A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6401028B2 (en) * 2014-11-27 2018-10-03 Ｓｈｉｏｄａライフサイエンス株式会社 Medium / long-term memory disorder prevention / improvement agent consisting of whale muscle extract
JP6550357B2 (en) * 2016-08-24 2019-07-24 日本ハム株式会社 An agent for inducing expression of a gene such as neurotrophic factor in glial cells, comprising an imidazole dipeptide
JP7134607B2 (en) * 2016-08-25 2022-09-12 大正製薬株式会社 tablet
JP6510004B2 (en) * 2016-11-15 2019-05-08 日本ハム株式会社 Exosome modulator containing imidazole dipeptide, and nerve cell activator containing exosome
US11148118B2 (en) * 2017-10-13 2021-10-19 W.M. Barr & Company, Inc. Encapsulated fragrance in compressed tablet
JP7251036B2 (en) * 2018-06-28 2023-04-04 ポーラ化成工業株式会社 Screening method for skin aging improving agent
WO2020085459A1 (en) * 2018-10-26 2020-04-30 国立大学法人東京大学 Antioxidation agent, antiglycation agent or anti-inflammatory agent
JP7321017B2 (en) * 2019-07-17 2023-08-04 東海物産株式会社 functional food
EP4081303A4 (en) * 2019-12-27 2024-01-24 Suntory Holdings Ltd Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract
CA3218849A1 (en) * 2021-05-14 2022-11-17 University Of Rochester Variants of sirt6 for use in preventing and/or treating age-related diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960010020A (en) * 1994-09-09 1996-04-20 도리이 신이치로 Hematopoietic antihypertensives
ATE332127T1 (en) * 1994-11-08 2006-07-15 Avicena Group Inc USE OF CREATINE OR CREATINENOLOGIST TO TREAT HUNTINGTON CHOREA, PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLERosis
JP2000116987A (en) 1998-10-15 2000-04-25 Sanyo Electric Co Ltd Detergent dissolving apparatus and washing machine with the same and static dissolver
JP4023648B2 (en) 1999-01-13 2007-12-19 日本ハム株式会社 Skin metabolism promoter and functional food
WO2001032168A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
KR20020044740A (en) * 2000-12-06 2002-06-19 강경선 Preventive and therapeutic agents for apoptosis-related diseases which contain carnosine as a pharmaceutically active ingredient
EP1285654B1 (en) * 2001-03-16 2006-06-07 Suntory Limited Autonomic system controlling agents and health drinks and foods
US6498498B1 (en) * 2001-06-27 2002-12-24 Intel Corporation Apparatus and method for applying reciprocity to frequency-domain noise analysis
WO2003013514A1 (en) * 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
JP2007070316A (en) 2005-09-09 2007-03-22 Nippon Meat Packers Inc Peroral composition and dietary supplement
WO2007116987A1 (en) * 2006-03-31 2007-10-18 Nippon Meat Packers, Inc. Functional food and drug having learning function-improving effect and antidepressant effect

Also Published As

Publication number Publication date
US20170165314A1 (en) 2017-06-15
ES2879329T3 (en) 2021-11-22
JP2015193582A (en) 2015-11-05
EP3124034B1 (en) 2021-04-21
EP3124034A1 (en) 2017-02-01
KR20160146760A (en) 2016-12-21
KR20220164079A (en) 2022-12-12
EP3124034A4 (en) 2018-03-21
SG11201608027RA (en) 2016-11-29
US20180140655A1 (en) 2018-05-24
WO2015146522A1 (en) 2015-10-01
CN106413733A (en) 2017-02-15

Similar Documents

Publication Publication Date Title
SG10201808208PA (en) Agent comprising imidazole dipeptide
IL258101A (en) Device and system for analyzing a sample, particularly blood, as well as methods of using the same.
WO2018132635A8 (en) Methods for analyzing t cell receptors and b cell receptors
SG10201805290YA (en) System and method for evaluation of used components
MX2022013114A (en) mTORC1 INHIBITORS.
MY187486A (en) Cysteine protease
PH12015502246A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
MY188696A (en) Cysteine protease
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2019000088A (en) Compositions and methods for detecting and treating diabetes.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
EP4218790A8 (en) Modulators of complement activity
MD3258919T3 (en) Nasal powder formulation for treatment of hypoglycemia
TR201818825T4 (en) LNCRNAS FOR THE TREATMENT AND DIAGNOSIS OF CARDIAC HYPERTROPHY
SG10201907901XA (en) Antibodies, uses & methods
MX2015015162A (en) Uric acid level lowering agent.
MX2016008638A (en) Powdery, musky odorant macrocycles.
PH12017501240B1 (en) Methods for detecting a marker for active tuberculosis
EP3616802A4 (en) Scale composition determination system, scale composition determination method, and program
MX2017006970A (en) Cellular-based method for determining the potency of defibrotide.
MX2018004474A (en) Anti-cd43 antibody and use thereof for cancer treatment.
NZ714014A (en) Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
MX2015016256A (en) Method for liquid authentication by detection of flavonoid derivatives.
EA033064B1 (en) Crystalline compound as semicarbazide-sensitive amine oxidase (ssao) enzyme inhibitor
DK178759B1 (en) A method for automatically presenting to a user online content based on the user's preferences as derived from the user's online activity